Prospective evaluation of an in-centre conversion from conventional haemodialysis to an intensified nocturnal strategy

Nephrology Dialysis Transplantation

Volumn 24, Issue 7, 2009, Pages 2232-2240

  David, Sascha ^a   Kümpers, Philipp ^a   Eisenbach, Georg M ^a   Haller, Hermann ^a   Kielstein, Jan T ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Anaemia; Blood pressure; Calcium phosphate product; Hyperparathyroidism; Nocturnal haemodialysis

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; AMLODIPINE; ANTIHYPERTENSIVE AGENT; BISOPROLOL; C REACTIVE PROTEIN; CALCIUM; CALCIUM ACETATE; CANDESARTAN; CARVEDILOL; DILTIAZEM; ENALAPRIL; ERYPRO; HEMOGLOBIN; IRON; LANTHANUM CARBONATE; LERCANIDIPINE; LOSARTAN; METOPROLOL; MOXONIDINE; NEBIVOLOL; NITRENDIPINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; PROTEIN; RAMIPRIL; RECOMBINANT ERYTHROPOIETIN; SEVELAMER; TRANSFERRIN; UNCLASSIFIED DRUG;

ADULT; ANTIHYPERTENSIVE DRUG SCORE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BIOELECTRICAL IMPEDANCE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; EVALUATION; EXTRACELLULAR SPACE; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPEDANCE; LONGITUDINAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM;

ADULT; HUMANS; LONGITUDINAL STUDIES; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 67651085540     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp029     Document Type: Article

References (39)

1. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019
2. McFarlane PA, Bayoumi AM, Pierratos A et al. The impact of home nocturnal hemodialysis on end-stage renal disease therapies: a decision analysis. Kidney Int 2006; 69: 798-805
3. Walsh M, Culleton B, Tonelli M et al. A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int 2005; 67: 1500-1508
4. Charra B, Calemard E, Ruffet M et al. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41: 1286-1291
5. Haag-Weber M. Treatment options to intensify hemodialysis. Kidney Blood Press Res 2003; 26: 90-95
6. Mahadevan K, Pellicano R, Reid A et al. Comparison of biochemical, haematological and volume parameters in two treatment schedules of nocturnal home haemodialysis. Nephrology (Carlton) 2006; 11: 413-418
7. Kleophas W, Reichel H. International study of health care organization and financing: development of renal replacement therapy in Germany. Int J Health Care Finance Econ 2007; 7: 185-200
8. Flanigan MJ, Khairullah QT, Lim VS. Dialysate sodium delivery can alter chronic blood pressure management. AmJKidneyDis 1997; 29: 383-391
9. Jacobs C, Frei D, Perkins AC. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant 2005; 20 (Suppl 3)iii3-iii24
10. Daugirdas JT, Depner TA, Gotch FA et al. Comparison of methods to predict equilibrated Kt/V in the HEMO Pilot Study. Kidney Int 1997; 52: 1395-1405
11. European best practice guidelines for haemodialysis (Part 1). Nephrol Dial Transplant 2002; 17(Suppl 7): 25
12. Hemodialysis Clinical Practice Guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 2006; 17(Suppl 1): S1
13. K/DOQI. Clinical Practice Guidelines and Clinical Practice Recommendations 2006 Updates: hemodialysis adequacy, peritoneal dialysis adequacy and vascular access. Am J Kidney Dis 2006; 48(Suppl 1): S1-S322
14. Kuhlmann MK, Zhu F, Seibert E, Levin NW. Bioimpedance, dry weight and blood pressure control: new methods and consequences. Curr Opin Nephrol Hypertens 2005; 14: 543-549
15. Levin NW, Zhu F, Seibert E et al. Use of segmental multifrequency bioimpedance spectroscopy in hemodialysis. Contrib Nephrol 2005; 149: 162-167
16. David S, Kumpers P, Seidler V et al. Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dys-function in patients with chronic kidney disease stage 5 on haemodialysis. Nephrol Dial Transplant 2008; 23: 1370-1377
17. Plum J, Schoenicke G, Kleophas W et al. Comparison of body fluid distribution between chronic haemodialysis and peritoneal dialysis patients as assessed by biophysical and biochemical methods. Nephrol Dial Transplant 2001; 16: 2378-2385
18. Katzarski KS, Charra B, Luik AJ et al. Fluid state and blood pressure control in patients treated with long and short haemodialysis. Nephrol Dial Transplant 1999; 14: 369-375
19. KDOQI. Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: 471-530
20. Ledebo I, Lameire N, Charra B et al. Improving the outcome of dialysis-opinion vs scientific evidence. Report on the Dialysis Opinion Symposium at the ERA-EDTA Congress, 6 September 1999, Madrid. Nephrol Dial Transplant 2000; 15: 1310-1316
21. Culleton BF, Walsh M, Klarenbach SW et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 2007; 298: 1291-1299
22. O'Sullivan DA, McCarthy JT, Kumar R et al. Improved biochemical variables, nutrient intake, and hormonal factors in slow nocturnal hemodialysis: a pilot study. Mayo Clin Proc 1998; 73: 1035-1045
23. Pierratos A, Ouwendyk M, Francoeur R et al. Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol 1998; 9: 859-868
24. Mucsi I, Hercz G, Uldall R et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 1998; 53: 1399-1404
25. Laurent G, Charra B. The results of an 8 h thrice weekly haemodialysis schedule. Nephrol Dial Transplant 1998; 13(Suppl 6): 125-131
26. Eloot S, Van Biesen W, Dhondt A et al. Impact of hemodialysis duration on the removal of uremic retention solutes. Kidney Int 2008; 73: 765-770
27. Kielstein JT, Kretschmer U, Ernst T et al. Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study. Am J Kidney Dis 2004; 43: 342-349
28. Lim VS, Bier DM, Flanigan MJ et al. The effect of hemodialysis on protein metabolism. A leucine kinetic study. J Clin Invest 1993; 91: 2429-2436
29. Wolfson M, Jones MR, Kopple JD. Amino acid losses during hemodialysis with infusion of amino acids and glucose. Kidney Int 1982; 21: 500-506
30. Al-Hejaili F, Kortas C, Leitch R et al. Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration. J Am Soc Nephrol 2003; 14: 2322-2328
31. Toussaint N, Boddington J, Simmonds R et al. Calcium phosphate metabolism and bone mineral density with nocturnal hemodialysis. Hemodial Int 2006; 10: 280-286
32. Toussaint ND, Polkinghorne KR, Kerr PG et al. Comparison between different dialysate calcium concentrations in nocturnal hemodialysis. Hemodial Int 2007; 11: 217-224
33. Van Eps CL, Jeffries JK, Anderson JA et al. Mineral metabolism, bone histomorphometry and vascular calcification in alternate night nocturnal haemodialysis. Nephrology (Carlton) 2007; 12: 224-233
34. Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome - the heart of the matter. Nephrol Dial Transplant 2002; 17(Suppl 11): 28-31
35. Locatelli F, Pozzoni P, Tentori F et al. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrol Dial Transplant 2003; 18(Suppl 7): vii2-vii9
36. Pecoits-Filho R, Goncalves S, Barberato SH et al. Impact of residual renal function on volume status in chronic renal failure. Blood Purif 2004; 22: 285-292
37. Costa E, Lima M, Alves JM et al. Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. J Clin Immunol 2008; 28(3): 268-275
38. Kalantar-Zadeh K, Stenvinkel P, Pillon L et al. Inflammation and nutrition in renal insufficiency. Adv Ren Replace Ther 2003; 10: 155-169
39. Kliger AS. High-frequency hemodialysis: rationale for randomized clinical trials. Clin J Am Soc Nephrol 2007; 2: 390-392